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Abstract
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many
patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy. Bone marrow studies have
shown that this residual disease resides within the stem cell compartment. Quiescence of leukemic stem cells has been
suggested as a mechanism conferring insensitivity to imatinib, and exposure to the Granulocyte-Colony Stimulating Factor
(G-CSF), together with imatinib, has led to a significant reduction in leukemic stem cells in vitro. In this paper, we design a
novel mathematical model of stem cell quiescence to investigate the treatment response to imatinib and G-CSF. We find
that the addition of G-CSF to an imatinib treatment protocol leads to observable effects only if the majority of leukemic
stem cells are quiescent; otherwise it does not modulate the leukemic cell burden. The latter scenario is in agreement with
clinical findings in a pilot study administering imatinib continuously or intermittently, with or without G-CSF (GIMI trial).
Furthermore, our model predicts that the addition of G-CSF leads to a higher risk of resistance since it increases the
production of cycling leukemic stem cells. Although the pilot study did not include enough patients to draw any conclusion
with statistical significance, there were more cases of progression in the experimental arms as compared to continuous
imatinib. Our results suggest that the additional use of G-CSF may be detrimental to patients in the clinic.
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Introduction
The existence of cancer stem cells, a rare subpopulation of cancer
cells responsible for tumor initiation and maintenance, was first
postulated in the 1960s [1]. In leukemia in particular, increasing
evidence suggests that leukemic stem cells are the only cells within
the tumor capable of propagating the disease [2–6]. Leukemic stem
cells share many properties – such as self-renewal, pluripotency, and
quiescence – with tissue stem cells, and they appear to remain
untouched by both conventional chemotherapy and targeted drugs
[6]. Since the repopulating capabilities of leukemic stem cells
necessitate their eradication for a cure of the disease, the
development of new therapeutic approaches targeting leukemic
stem cells would have a profound impact on cancer management.
Chronic myeloid leukemia (CML) is associated with the
Philadelphia chromosome, which results from a reciprocal
translocation between chromosomes 9 and 22 generating the
BCR-ABL fusion oncogene [7,8]. The ABL kinase inhibitor
imatinib greatly improves outcome in CML patients [9]; however,
some evidence suggests that it cannot eradicate the disease since it
preferentially targets progenitor cells while being incapable of
depleting leukemic stem cells [10]. Surviving leukemic stem cells
are a potential source of relapse, as demonstrated by the dynamics
of leukemic cells in patients who discontinue imatinib after a
prolonged administration of therapy [11–17]. Several mechanisms
of leukemic stem cell insensitivity to ABL kinase inhibitors have
been suggested [18]; those mechanisms include quiescence of
leukemic stem cells, drug export from the cytoplasm, overexpres-
sion of BCR-ABL in stem cells as compared to differentiated cells,
and a lack of immune responses against leukemic stem cells.
Under normal circumstances, a fraction of hematopoietic stem
cells is quiescent [19–24]. Cycling and quiescent hematopoietic
stem cells display major functional differences, mostly reflected in
their homing and mobilization abilities [25–29]. Quiescent stem
cells are mobilized by Granulocyte-Colony Stimulating Factor (G-
CSF) and other agents and show preferential homing to the bone
marrow as compared to dividing hematopoietic stem cells [29]. In
contrast, CML stem cells are constitutively present in the
circulation, but also contain a subpopulation of quiescent cells
[30]. This quiescent subpopulation has been shown to be insensitive
to imatinib therapy in vitro and might therefore represent a
therapeutically relevant subpopulation of cancer cells [31].
However, the extent of quiescence of CML stem cells and the in
vivo response of such cells to imatinib have not yet been established.
In this paper, we present a novel mathematical model to
investigate the response of cycling and quiescent leukemic stem
cells to treatment with imatinib alone or imatinib combined with
G-CSF. We use clinical data of a Phase II trial administering
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imatinib and G-CSF and study the effects of various treatment
strategies on the leukemic stem cell pool [32]. This study is part of
a growing literature of theoretical approaches to CML [16,33–39].
Methods
Mathematical Modeling of the CML Cell Hierarchy,
Turnover, and Response to Imatinib
Consider a differentiation hierarchy of hematopoietic cells. On
top of the hierarchy, there are cycling and quiescent stem cells.
Quiescent stem cells can become cycling stem cells, while the latter
can become quiescent stem cells. Cycling stem cells give rise to
progenitor cells, which produce differentiated cells, which in turn
produce terminally differentiated cells (Fig. 1A). This differentiation
hierarchy applies to normal and leukemic cells [40]. The abundances
of normal cycling and quiescent stem cells, progenitors, differenti-
ated, and terminally differentiated cells are denoted by x0, xq, x1, x2,
and x3; the respective abundances of leukemic cells are denoted by
y0, yq, y1, y2, and y3. Normal and leukemic cycling stem cells divide
at rates rx and ry, respectively. The rates at which cycling stem cells
produce quiescent stem cells and vice versa are denoted by a and b.
The rate constants for the production of progenitors, differentiated
cells and terminally differentiated cells are given by a, b, and c.
Cycling stem cells die at rate d0, progenitors at rate d1, differentiated
cells at rate d2, and terminally differentiated cells at rate d3 per day.
Here we assume that cells at all levels may reproduce symmetrically
and/or asymmetrically; the limited replication potential of more
differentiated cell types can be considered as part of the
differentiation rates. The BCR-ABL oncogene is present in all
leukemic cells and leads to a slow clonal expansion of cycling
leukemic stem cells; the latter effect is assumed since otherwise,
leukemic stem cells could not make up a significant fraction of the
stem cell compartment at diagnosis [30,41]. Furthermore, BCR-
ABL increases the rate at which leukemic progenitors are produced.
The basic model is displayed in Table 1. Density dependence is
achieved by the functions Qx~1=½1zpx(x0zy0) and
Qy~1=½1zpy(x0zy0); these functions ensure that normal and
leukemic stem cells remain at a constant abundance once the system
has reached a steady state. To achieve realistic equilibrium
conditions, we set the constants px~(rx=d0{1)=x
q
0 and
py~(ry=d0{1)=y
q
0, where x
q
0 and y
q
0 are the equilibrium abun-
dances of normal and leukemic stem cells, respectively. In the
absence of leukemic cells, the differentiation hierarchy of normal
cells is in equilibrium, i.e. the abundances and proportions of
different cell types do not change. Once the first leukemic stem cell
arises, it produces a differentiation hierarchy of leukemic cells. The
BCR-ABL oncogene is assumed to increase the rate at which
progenitors and differentiated cells are being produced, aywax and
bywbx. We assume that diagnosis occurs and treatment initiates
once the leukemic cell burden reaches a threshold of 1012 cells.
Imatinib therapy counteracts the effects of BCR-ABL by reducing
the differentiation rates to a0yvay and b
0
yvby, and possibly reducing
the growth rate of cycling leukemic stem cells to r’yƒry. These
effects result in distinct phases of exponential decline: (i) the first
phase, with a slope of {d3, represents the depletion of terminally
differentiated leukemic cells; since these cells have an average
lifespan of about a day, their depletion cannot be observed in clinical
data (IRIS trial) for reasons of low resolution [16]; (ii) the second
phase, with a slope of {d2, corresponds to the decline of
differentiated leukemic cells; this slope can be observed in the IRIS
data and has an average of d2~0:05 per day, suggesting that
differentiated cells live approximately 20 days during therapy; (iii) the
third phase, with a slope of{d1, signifies the depletion of leukemic
progenitors; this slope is about d1~0:008, representing a lifespan of
125 days for progenitors during treatment; and (iv) the fourth phase
reflects the effect of imatinib on cycling stem cells. If imatinib is
unable to deplete cycling leukemic stem cells (r’y~ry), then the
leukemic cell burden increases during the fourth phase, while it
decreases if imatinib is capable of depleting cycling leukemic stem
cells. The slope of the fourth phase of decline represents the rate of
decline of leukemic stem cells and is calculated in the following.
Denote by F (t)~y0(t)=½y0(t)zyq(t) the ratio of cycling to total
leukemic stem cells; the asymptotic value of this ratio during
treatment is given by F ’?. Note that if r’yvry, then F ’? is not the
same as the frequency of cycling stem cells at equilibrium (at which
the system is initiated), since in that case imatinib therapy
decreases the growth rate of cycling leukemic stem cells and
disturbs the equilibrium of the system. To calculate the fourth
slope, we isolate the two-dimensional system for (y0,yq) and
consider the differential equation in terms of the ratio
1=F (t)~1zyq=y0. As treatment is administered and time
increases, 1=F (t) approaches 1=F ’?, which is given by
1=F ’?~
{(r’yQy,?{d0)zayzbyz
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4by(r’yQy,?{d0)z({(r’yQy,?{d0)zayzby)
2
q
2by
,
where Qy,?~1=(1zpyX0  ) is the asymptotic value of Qy for
large times. The equilibrium carrying capacity of the healthy
cycling stem cells is given by X0 ~(rx{d0)bx=½pxd0(axzbx).
The slope of the fourth phase of decline of terminally differentiated
cancer cells is then given by (r’yQy,?{d0)F ’?. In Fig. 1B, we
show the dynamics of cells observed in peripheral blood if cycling
leukemic stem cells are slowly depleted by imatinib (lower line) and
if cycling leukemic stem cells continue to increase during therapy
(upper line).
Results
Parameter Sensitivity
Since the extent of quiescence among hematopoietic stem cells is
the subject of controversy [21–24], we test the sensitivity of the
model’s predictions to changes in parameters. The parameter
Author Summary
Imatinib mesylate (Gleevec) is currently the standard
treatment for chronic myeloid leukemia (CML) and elicits
a large reduction in leukemic cell burden in most patients.
However, strong evidence suggests that imatinib does not
cure the disease; approximately 20% of patients relapse
within three years, and discontinuation of imatinib therapy
often leads to a rebound of the leukemic cell burden.
Laboratory studies have suggested that there exists a
subpopulation of ‘‘quiescent’’ leukemia cells (i.e., cells that
do not divide) that may be insensitive to imatinib
treatment. It has been postulated that the disease
outcome may be improved by administering imatinib in
conjunction with the Granulocyte-Colony Stimulating
Factor (G-CSF), a growth factor which ‘‘wakes up’’ the
quiescent stem cells and sensitizes them to imatinib. In this
study, we design a novel mathematical model of stem cell
quiescence to investigate the treatment response to
imatinib and G-CSF. We find that adding G-CSF to an
imatinib treatment protocol leads to observable effects
only if the majority of leukemic stem cells are quiescent.
Our model also predicts that adding G-CSF leads to a
higher risk of resistance, since it increases the number of
leukemic stem cell divisions and thus the probability of
acquiring a resistance mutation.
Modeling CML Stem Cell Quiescence
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Figure 1. A mathematical model of chronic myeloid leukemia. (A) The model contains different subpopulations of the differentiation
hierarchy of hematopoietic cells. On top of the hierarchy, there are cycling and quiescent stem cells. Cycling stem cells can reproduce and also
produce progenitor cells. Progenitors give rise to differentiated cells, which produce terminally differentiated cells. (B) We show the simulation results
of the terminally differentiated leukemic cell population, y3 , during imatinib treatment which initiates on day 0. The leukemic cell burden declines in a
multi-phasic manner: terminally differentiated leukemic cells decrease at their death rate, d3~1 per day, until they reach a steady state with
differentiated leukemic cells, then they track the latter’s disease kinetics (slope not shown for reasons of low resolution of the data). Differentiated
leukemic cells decline at their death rate, d2~0:05 per day, until they reach an equilibrium with leukemic progenitors (green slope). Progenitors
decline at their death rate, d1~0:008 per day, until they reach an equilibrium with leukemic stem cells (blue slope). These slopes are estimated from
the IRIS data [16]. Leukemic stem cells increase or decline at a rate equal to the asymptotic value of (ryQy,?{d0)F ’?. In this figure, we show examples
of the kinetics in which leukemic stem cells are assumed to decrease during imatinib therapy (red slope), and in which leukemic stem cells continue
to increase during therapy (dashed line). Parameter values are rx~rx
0~0:005, ry~0:008, ry 0~0:002, ax~ay~0:0001, bx~by~0:0009, d0~0:003,
d1~0:008, d2~0:05, d3~1, ay~2ax, by~2bx, cy~cx, ay
0~ay=100, by 0~by=750, and cy 0~cy . The other parameters are calculated such that in
equilibrium, there are 1012 normal terminally differentiated cells, 1010 normal differentiated cells, 108 normal progenitors, and 106 normal and 107
leukemic stem cells (cycling plus quiescent). All parameters whose values during therapy are not specified are unaltered by treatment. Our parameter
choices set the initial equilibrium frequency of both normal and leukemic cycling stem cells to 90% (G~0:9).
doi:10.1371/journal.pcbi.1000503.g001
Modeling CML Stem Cell Quiescence
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G~bx=(axzbx) specifies the frequency of normal cycling stem
cells if the system is in equilibrium; if ax~ay and bx~by, then G
also denotes the equilibrium fraction of cycling leukemic stem cells.
The effects of varying G are shown in Fig. 2A where we plot the
abundances of various cell types prior to and during imatinib
therapy. Here we assume that diagnosis and treatment occur once
the leukemic cell burden reaches a threshold of 1012 cells. We may
also investigate the case in which the proportion of cycling stem cells
to total stem cells is different for leukemic (Gy) and normal (Gx) cells.
In Figure S1 we investigate the dynamics of the system during
imatinib therapy and during concurrent imatinib and G-CSF
treatment when GxvGy. While changes in G alter the abundance
of cycling and quiescent stem cells, they do not modify the
abundance of terminally differentiated leukemic cells by a
significant amount. A choice of G specifies the relationship between
the rate at which cycling stem cells produce quiescent stem cells, ax
and ay (for healthy and leukemic cells, respectively), and the rate at
which quiescent stem cells produce cycling stem cells, bx and by.
The effects of varying these turnover rates while keeping G fixed
prior to and during imatinib therapy are shown in Fig. 2B. The
abundance of terminally differentiated cells is even less sensitive to
such changes than to variation of G. Therefore, despite insufficient
knowledge about the extent and regulation of quiescence, a
sensitivity analysis of the system determines that the model’s
predictions are very robust with regard to changes in parameters
that determine the abundance and turnover of quiescent stem cells.
Clinical Trial Results
In light of in vitro data supporting such a strategy [42], a
randomized, phase II pilot clinical trial was commenced in 2004 to
establish the safety of pulsed imatinib in combination with G-CSF.
Imatinib interruption (for 1 week every 4 weeks) was deemed to be
necessary based upon in vitro data suggesting an anti-proliferative
effect of this strategy [31]. The trial was performed as a three arm,
multi-center study which enrolled 15 patients in each arm:
continuous imatinib (cIM) vs. pulsed IM (pIM) vs. pIM plus G-
CSF (pIM-G) given three times weekly during the period of dose
interruption. Results of the study have recently been published
[32]. Monthly Q-PCR monitoring was performed over the 12
month study period and the results are summarized in Figs. 3A
and 3B (unpublished observations). Although not powered to
detect small differences between the treatment arms over time, no
significant changes in BCR-ABL/ABL ratios (%) were noted over
the study period. Furthermore, 6 patients in the experimental arms
exhibited disease progression or loss of response, as compared to a
single patient in the control arm (cIM). While this was not in itself
statistically significant, the majority of these patients (5/7) had
disease control re-established by reintroduction of daily TKI
therapy suggesting that the experimental approach had contrib-
uted to the loss of response.
Application of the Model to Clinical Trial
Let us now use our mathematical model to predict the outcome
of the clinical trial described above [32]. First, we investigate the
dynamics of the system during combination therapy with imatinib
and G-CSF. G-CSF functions by mobilizing both healthy and
leukemic quiescent stem cells [29]. In the context of our model,
this effect corresponds to increasing bx and, to an even larger
extent, by. More specifically, we assume that G-CSF has a stronger
effect on leukemic stem cells than on healthy stem cells [42]. The
treatment response to imatinib alone and imatinib in combination
with G-CSF is shown in Fig. 4A, where the abundances of each
cell type are plotted as a function of time elapsed since the start of
therapy. We assume that imatinib has no effect on the normal
hematopoietic system (Fig. S2) and study two scenarios: (i) the
majority of stem cells (both normal and leukemic) are initially
quiescent [21,22], G~0:1, and (ii) the majority of stem cells are
cycling [23,24], G~0:9. In the latter case, the addition of G-CSF
does not change the dynamics of terminally differentiated cells
during therapy at all. If most stem cells are quiescent, however,
then the addition of G-CSF leads to an increase in cycling
leukemic stem cells since there is an enhanced production of
cycling stem cells from the quiescent pool; this effect translates into
higher levels of terminally differentiated cells during therapy.
Additionally, administration of G-CSF leads to an enhanced
production of normal cycling stem cells from the quiescent pool,
albeit to a lesser extent than in the leukemic system.
Next, we investigate the dynamics of the system during pulsed
imatinib therapy with and without G-CSF. In Fig. 4B, we compare
the effects of different treatment options on the abundance of
terminally differentiated cells. We perform the comparison for the
two cases in which the initial fraction of cycling stem cells is 10%
and 90%, respectively (G~0:1 and 0.9). The outcome of such
treatment choices is similar to the continuous treatment scenarios
shown in Fig. 4A: if G~0:9, then the effects of adding G-CSF are
negligible for the abundance of terminally differentiated leukemic
cells; if G~0:1, however, then the level of terminally differentiated
leukemic cells is higher when G-CSF is administered than when
imatinib is used alone.
So far we have found that depending on the abundance of
quiescent stem cells, the addition of G-CSF to the imatinib
treatment protocol either increases or does not affect the level of
terminally differentiated leukemic cells in the first 1500 days of
therapy. Note that these results are dependent upon our
assumption that imatinib treatment leads to a decline of leukemic
stem cells. We next investigate the long-term effects of continuous
imatinib treatment with and without G-CSF (Fig. 5A). The
addition of G-CSF is ultimately beneficial for the patient since it
decreases the leukemic cell burden at a faster rate than imatinib
therapy alone. However, for an intermediately long treatment
horizon, the additional administration of G-CSF increases the
Table 1. Basic model of differentiation hierarchy of normal and leukemic cells.
Normal Leukemic
Cycling stem cells _x0~½rxQx{d0{axx0zbxxq _y0~½ryQy{d0{ayy0zbyyq
Quiescent stem cells _xq~axx0{bxxq _yq~ayy0{byyq
Progenitors _x1~axx0{d1x1 _y1~ayy0{d1y1
Differentiated cells _x2~bxx1{d2x2 _y2~byy1{d2y2
Terminally diff. cells _x3~cxx2{d3x3 _y3~cyy2{d3y3
doi:10.1371/journal.pcbi.1000503.t001
Modeling CML Stem Cell Quiescence
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Figure 2. The effects of stem cell parameters on the model predictions. (A) We show the sensitivity of the model to the equilibrium
frequency of cycling stem cells, G. Initially, the healthy cells are in equilibrium and there is one leukemic stem cell. As the leukemic cell population
increases, the healthy cell population begins to decrease due to competition. Treatment is initiated once the leukemic cell burden has reached a
threshold of 1012 cells, at which point the leukemic cell burden begins to decline. Three scenarios are investigated: (i) the fraction of cycling stem cells
is 10%, G~0:1, using values of a~0:0009andb~0:0001 (blue lines), (ii) the fraction of cycling stem cells is 50%, G~0:5, with a~0:0005andb~0:0005
(red lines), and (iii) the fraction of cycling stem cells is 90%, G~0:9, with a~0:0001andb~0:0009 (green lines). Here a~ax~ay and b~bx~by , with
all other parameters as in Fig. 1. (B) We show the sensitivity of the model to a and b (i) b~0:0009 (blue lines), (ii) b~0:009 (red lines), and (iii) b~0:09
(green lines); in all cases a is chosen such that G~0:9. Note the relative insensitivity of number of terminally differentiated leukemic cells to a and b.
doi:10.1371/journal.pcbi.1000503.g002
Modeling CML Stem Cell Quiescence
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Figure 3. Results of a clinical trial administering continuous imatinib, pulsed imatinib, and pulsed imatinib with G-CSF.We show box
and whisker plots of log BCR-ABL/ABL (%) levels (A) and plots of median log BCR-ABL/ABL (%) levels (B) for each study arm of the GIMI trial (see text for
trial description). No significant differences were observed at cycles 1 (C1) or 12 (C12) as compared to baseline for either the pulsed imatinib arm or
the pulsed imatinib with G-CSF when compared to the arm administering continuous imatinib as shown in (A) (p-values all.0.1). The trendlines in (B)
demonstrate no significant differences between the arms when changes from baseline were compared (p-values all.0.1). ANCOVA analysis was used
thereby adjusting results by their baseline values. Note that the average levels of patients in the pulsed imatinib arm and the pulsed imatinib with G-
CSF arm differed at the outset of the trial but did not change during the study period. IM, imatinib mesylate; G, G-CSF.
doi:10.1371/journal.pcbi.1000503.g003
Modeling CML Stem Cell Quiescence
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Figure 4. Treatment with imatinib and G-CSF. (A) The dynamics of the hematopoietic system during therapy with imatinib alone (blue and red
lines) or imatinib in combination with G-CSF (green and orange lines) are shown. We investigate the system for two different equilibrium frequencies
of cycling stem cells: G=0.1 (blue and green lines), and G=0.9 (red and orange lines). The addition of G-CSF has an effect on the abundance of
terminally differentiated cells only if the fraction of cycling stem cells is small, G=0.1. Parameter values during imatinib and G-CSF combination
therapy are b’’x~2bx and b’’y~8by ; all other parameters are as in Fig. 2. (B) The dynamics of the hematopoietic system during therapy with pulsed
imatinib (3 weeks on, one week off; blue and red lines) or imatinib alternating with G-CSF (3 weeks imatinib, one week G-CSF; green and orange lines)
are shown. We investigate the system for two different equilibrium frequencies of cycling stem cells: G= 0.1 (blue and green lines), and G= 0.9 (red
and orange lines). Again, the addition of G-CSF has an effect only if G= 0.1. Parameter values during G-CSF therapy are as above.
doi:10.1371/journal.pcbi.1000503.g004
Modeling CML Stem Cell Quiescence
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Figure 5. Long-term effects of therapy. (A) We show the long-term dynamics of leukemic cells in peripheral blood, BCR-ABL/BCR (%), during
continuous imatinib therapy with (red line) and without (blue line) G-CSF. We plot y3=(2x3zy3) since normal cells have two alleles of BCR while
leukemic cells have only one. Treatment starts on day zero and leads to a tri-phasic depletion of the leukemic cell burden if imatinib is capable of
depleting leukemic stem cells. Although the addition of G-CSF initially increases the number of terminally differentiated leukemic cells, the long-term
trend reveals that adding G-CSF does result in a faster rate of depletion of the leukemic cell burden and eventually leads to smaller numbers of
terminally differentiated leukemic cells. The initial equilibrium frequency of cycling stem cells is G~0:5 with a~0:0005 and b~0:0005 (all other
parameters are as in Fig. 4). (B) We show the long-term simulation results for the number of leukemic stem cell divisions during continuous imatinib
therapy with (red line) and without (blue line) G-CSF. This number is directly proportional to the risk of resistance to therapy. Until the crossover point
of about 10,000 days, imatinib therapy leads to a lower number of stem cell divisions and therefore to a lower probability of resistance. After the
crossover point, combination therapy with imatinib and G-CSF leads to a lower risk of resistance. All parameter values are as above.
doi:10.1371/journal.pcbi.1000503.g005
Modeling CML Stem Cell Quiescence
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leukemic cell burden since G-CSF enhances the production of
cycling leukemic stem cells from their quiescent counterparts. This
increased frequency of cycling stem cells allows for an enhanced
effect of imatinib, leading to an exhaustion of both cycling and
quiescent stem cells.
The evolution of point mutations in the BCR-ABL kinase
domain conferring resistance represents a limitation for the
usefulness of imatinib therapy [43–47]. We sought to investigate
whether the addition of G-CSF to imatinib treatment modulates
the risk of resistance in treated patients. Denote by B(t) the
number of cell divisions of leukemic stem cells until time t; this
quantity can be calculated as B(t)~
ðt
0
r’yy0(s)ds, which depends
on the effects of imatinib (and G-CSF) therapy. The probability
that a point mutation conferring resistance arises per stem cell
division is denoted by m. Here we assume that only leukemic stem
cells can accumulate resistance mutations since they are the only
cells that have self-renewal potential; if a resistance mutation arises
in a progenitor or differentiated cell, then this resistant cell cannot
produce a self-sufficient clone and will eventually die out. We also
only consider resistance arising due to BCR-ABL kinase domain
mutations and exclude other reasons for the emergence of resistance
from our analysis. Then the probability that at least one resistant
leukemic stem cell has arisen in a patient before time t is given by
P(t)~1{exp½{mB(t). Thus a larger B(t) results in a higher risk of
developing resistance by time t. Note that this probability includes
only newly emerging resistance and does not capture the risk of
resistance due to mutations present prior to the initiation of therapy;
since we are interested only in the effects of different treatment
protocols on the risk of resistance and we assume complete
resistance, we can neglect the latter type of mutations. In Fig. 5B
we show the number of leukemic stem cell divisions, B(t), as a
function of time for treatment with imatinib alone or in combination
with G-CSF. There exists a crossover point in time, prior to which
patients have a lower probability of developing resistance during
imatinib therapy. Beyond the crossover point, combination therapy
leads to a lower probability of resistance.
As a numerical example, consider the risk of resistance for
patients 2500 days (,6.8 yrs) after the initiation of therapy. If
resistance can emerge due to any one out of 90 different point
mutations in the BCR-ABL kinase domain and the baseline
mutation rate is 10{7 per base per cell division [48], then the
probability that a resistance mutation arises per cell division is
90:10{7. The model predicts that 89 out of every 100 patients
would develop resistance if treated with imatinib alone, whereas
96 out of every 100 patients would develop resistance if treated
with imatinib and G-CSF. If we assume a baseline point mutation
rate of 10{8 per cell division, then 20 out of 100 patients on
imatinib and 27 out of 100 patients on imatinib and G-CSF would
develop resistance during the first 2500 days of therapy. Our
model predicts that patients on combination therapy who do not
develop resistance will benefit from the later effects of G-CSF that
reduce the levels of leukemic cells in the blood; however, they will
remain at prolonged elevated risk of resistance in comparison to
patients on imatinib therapy until the crossover point.
Similarly to the risk of resistance, we can also consider the risk of
progression to accelerated phase and blast crisis during different
treatment options. Using the model designed in [38], we predict that
the rate of progression is lowest during treatment strategies that
most effectively deplete progenitor cells if blast crisis stem cells arise
from the progenitor pool [49]. Therefore, a treatment strategy that
increases cycling leukemic stem cells and progenitors even
transiently (such as G-CSF therapy) will increase the initial risk of
progression to blast crisis. If G-CSF administration additionally
protects progenitor cells from being inhibited by imatinib therapy
[50], then the risk of progression is even more pronounced.
Discussion
In this paper, we have presented a novel mathematical model of
the hematopoietic system of CML patients during therapy. We
have used this model to investigate the response to treatment with
imatinib and/or the growth factor G-CSF. We have studied four
different treatment strategies: (i) continuous administration of
imatinib alone; (ii) continuous administration of combination
therapy with imatinib and G-CSF; (iii) pulsed imatinib followed by
a treatment break; and (iv) pulsed imatinib followed by G-CSF
therapy. The capability of G-CSF therapy to modulate the
leukemic cell burden depends on the extent of quiescence among
leukemic stem cells: if the majority of leukemic stem cells are
quiescent, then the addition of G-CSF to imatinib therapy
temporarily increases the leukemic cell burden in peripheral
blood. Eventually this treatment strategy leads to a more rapid
decline of leukemic cells. However, this effect is only observed if
imatinib is capable of depleting cycling leukemic stem cells. If
cycling stem cells are insensitive to imatinib in vivo, then the
addition of G-CSF will only increase the leukemic cell burden.
Furthermore, we have not considered a protective effect of G-CSF
on leukemic stem cells [50] since cytokines seem to protect only
bulk CD34+ cells from tyrosine kinase inhibition and about 10%
of primitive CML stem cells survive a 12 day exposure to dasatinib
in the absence of any added cytokines [51]. However, the inclusion
of such an effect would make our conclusion even stronger that the
addition of G-CSF to tyrosine kinase inhibitor (TKI) therapy may
not be beneficial in the clinic.
The effects of therapy with continuous and pulsed imatinib as
well as pulsed imatinib with G-CSF have been investigated in a
pilot study in 2009 [32]. Forty-five patients were randomized
between three treatment arms: continuous imatinib, pulsed
imatinib, and pulsed imatinib with G-CSF. Since the patients
recruited to participate in this pilot study were not newly
diagnosed but already pre-treated with imatinib, their cell counts
had already reached the fourth phase in the dynamics (see Fig. 1B).
Our mathematical model predicts differences in the leukemic cell
burden between patients on imatinib therapy with and without G-
CSF only if the majority of leukemic stem cells are quiescent
(Fig. 4). If most leukemic stem cells are cycling, then the addition
of G-CSF to imatinib therapy is expected to have no appreciable
effect on the BCR-ABL RQ-PCR levels. This situation was
observed in the pilot study [32], suggesting that the majority of
leukemic stem cells are cycling. This conclusion, however, can
only be drawn if imatinib is capable of inhibiting cycling leukemic
stem cells.
Lastly, we have determined the risk of resistance arising during
imatinib therapy with and without G-CSF. While treatment with
imatinib alone eventually leads to a higher risk of resistance,
combination therapy with imatinib and G-CSF initially confers a
larger probability of acquired resistance. A similar conclusion can
be drawn regarding the risk of progression to accelerated phase
and blast crisis.
Since the trial was designed to investigate the safety of this
treatment protocol and was not powered for efficacy, the
conclusions about response and disease progression should not
be over-interpreted. Although the PCR values over time were not
significantly different between the three treatment arms, the
continuous imatinib arm tended downwards during the duration
of the trial, while the other two arms did not show any increases or
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decreases in leukemic cell burden (Fig. 3B). This observation is
expected from the model since discontinuous administration of
imatinib should show a smaller effect on the disease burden than
continuous administration if imatinib therapy is capable of
inhibiting leukemic stem cells. Also, 6 of 7 cases showing disease
progression were in the pulsed treatment arms; this effect is also in
concordance with our model’s prediction since the risk of
resistance is directly correlated with the number of leukemic stem
cells which, if sensitive to imatinib, are less abundant in patients
receiving continuous therapy than in those receiving pulsed doses.
Our findings regarding the risk of resistance and progression
together with the absence of a clinical response with the addition
of G-CSF suggest that this treatment option may not be beneficial
for CML patients in the clinic.
Supporting Information
Figure S1 Equilibrium frequency of normal vs. leukemic cycling
stem cells. We compare dynamics of the model in two cases: (i) the
frequency of cycling leukemic stem cells, Gy= 0.9, is greater than
the frequency of cycling healthy stem cells, Gx= 0.5, and (ii) the
cycling frequencies of normal and leukemic stem cells are the same
(Gx=Gy=0.9). All other parameter values are as above. In (A) we
show the model predictions prior to and during continuous
imatinib therapy, and in (B) we show the analogous results for
continuous imatinib plus G-CSF therapy. Note that although the
change in Gx changes the abundances of quiescent and cycling
normal stem cells, we do not see much change in the total
leukemic cell burden in either case.
Found at: doi:10.1371/journal.pcbi.1000503.s001 (1.01 MB TIF)
Figure S2 Effect of imatinib on normal hematopoietic stem cells.
We investigate the dynamics of the model if imatinib has the
additional effect of slightly lowering the growth rate of normal
hematopoietic stem cells (rx’ = 0.0045,rx= 0.005) and compare
this situation to the case when imatinib has no effect on these cells
(rx’ = rx = 0.005). We observe that this modification does not
significantly alter the leukemic cell burden.
Found at: doi:10.1371/journal.pcbi.1000503.s002 (0.86 MB TIF)
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